FCGBP Gene Variant Linked to Lung Transplant Complications

Recent advances in lung transplantation highlight both clinical and genetic factors influencing patient outcomes. A new Composite Allocation Score (CAS) implemented in 2023 improved access for marginalized groups, reduced waitlist mortality, and enhanced one-year survival rates by enabling longer transport distances and increased use of donation after circulatory death with normothermic regional perfusion. Clinically, lung transplantation in patients with rare coagulation disorders like congenital alpha-2 plasmin inhibitor deficiency has been successfully performed using prophylactic fresh frozen plasma and tranexamic acid, supported by point-of-care coagulation testing. Genetically, researchers at Pusan National University identified a mutation in the FCGBP gene strongly associated with bronchiolitis obliterans syndrome (BOS), a severe post-transplant complication causing airway narrowing and graft failure. This FCGBP variant correlates with higher risks of BOS, infections, and rejection, offering potential for preoperative genetic screening to tailor treatments and improve outcomes. The discovery bridges genetic factors with clinical management, promising better prediction and prevention of complications following lung transplantation.